Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals
NYSE | Common Stock
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States.
The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages.
It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications.
The company's product portfolio includes Amphetamine IR tablets, Amphetamine ER capsules, Dicyclomine tablets, Fluphenazine tablets, Levothyroxine capsules, Methylphenidate CD capsules, Methylphenidate ER, Posaconazole DR tablets, Probenecid tablets, and Verapamil SR tablets, as well as Numbrino nasal solution.
It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations.
The company has supply and development agreements with Summit Bioscience LLC, Sinotherapeutics, Respirent Pharmaceuticals Co., Ltd., HEC Pharm Group, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies.
Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 3, 23 | 0.00 Increased by +100.00% | -0.39 Increased by +100.00% |
| Feb 1, 23 | -1.36 Increased by +12.82% | -1.64 Increased by +17.07% |
| Nov 2, 22 | -1.68 Decreased by -55.56% | -1.82 Increased by +7.69% |
| Aug 24, 22 | -1.76 Decreased by -131.58% | -1.84 Increased by +4.35% |
| May 4, 22 | -1.64 Decreased by -2.15 K% | -1.70 Increased by +3.53% |
| Feb 3, 22 | -1.56 Decreased by -587.50% | -1.28 Decreased by -21.88% |
| Nov 3, 21 | -1.08 Decreased by -550.00% | -0.98 Decreased by -10.20% |
| Aug 25, 21 | -0.76 Decreased by -161.29% | -0.47 Decreased by -61.70% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 80.51 M Increased by +2.74% | -101.47 M Decreased by -190.76% | Decreased by -126.04% Decreased by -183.00% |
| Dec 31, 22 | 80.89 M Decreased by -6.49% | -36.31 M Increased by +55.22% | Decreased by -44.88% Increased by +52.11% |
| Sep 30, 22 | 75.08 M Decreased by -26.05% | -28.02 M Decreased by -25.41% | Decreased by -37.32% Decreased by -69.58% |
| Jun 30, 22 | 74.19 M Decreased by -30.02% | -93.30 M Increased by +47.55% | Decreased by -125.75% Increased by +25.06% |
| Mar 31, 22 | 78.36 M Decreased by -30.27% | -34.90 M Decreased by -388.63% | Decreased by -44.54% Decreased by -600.73% |
| Dec 31, 21 | 86.51 M Decreased by -35.40% | -81.08 M Increased by +52.84% | Decreased by -93.73% Increased by +27.00% |
| Sep 30, 21 | 101.53 M Decreased by -19.73% | -22.34 M Decreased by -243.78% | Decreased by -22.01% Decreased by -328.27% |
| Jun 30, 21 | 106.01 M Decreased by -23.14% | -177.89 M Decreased by -1.73 K% | Decreased by -167.80% Decreased by -2.29 K% |